ClinicalTrials.gg
RecruitingNCT06651112ATPUpdated Oct 26, 2026

The ATP Project (Antipsychotic-TEP-Psychosis)

An observational study in First Episose Psychosis, Metabolic Disease and Psychosis; Episode, sponsored by Université de Sherbrooke. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Université de Sherbrooke · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
18
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Metabolic Diseases with a site in Canada — 15 open to participants now, 24 under way, 8 of them phase 3. Metabolic Diseases · Canada.

Started
2024
with 9 others
Observational
9 of 67
1 open now
Primary completion
2027-12
later than 16 of 23 live
Registered
63rd of 67
by date

Among the 67 studies in Metabolic Diseases with a site in Canada, this one is one of 10 that started in 2024, is one of 9 observational ones, reaches primary completion later than 16 of the 23 other live ones, and was the 63rd registered.

Metabolic Diseases

765 studies on the registry are indexed under Metabolic Diseases; 194 are open to participants now.

Browse Metabolic Diseases studies →

Open to participants now

15 of the 67 studies in Metabolic Diseases with a site in Canada are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 135 Metabolic Diseases studies recruiting now, 47 (35%) set no upper age limit and 64 (47%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Metabolic Diseases with a site in Canada, or all of them as a file.
02

Study summary

The goal of this observational study is to the early impacts of psychosis and antipsychotic medications on brain metabolism in young adults recently diagnosed with a first episode of psychosis.

The main question aims to evaluate the effect of 4 to 6 weeks of antipsychotic medication on brain metabolism measured by PET scan (cerebral uptake of 11C-Acetoacetate + 18 Fluorodeoxyglucose).

Participants will undergo a multimodal imaging protocol with other measures of psychopathology (e.g., cognition, depressive symptoms, etc.) and (metabolic marker, inflammation, etc).

03

Conditions studied

  • First Episose Psychosis
  • Metabolic Disease
  • Psychosis; Episode

Keywords

  • psychosis
  • cerebral metabolism
  • glucose
  • ketone
  • PET scan
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals aged 18 to 35 from the Estrie region who have been evaluated by the PEP team and wish to start an antipsychotic (AP) for the treatment of a first episode of psychosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admission to the PEP clinic in Estrie, either outpatient or inpatient, according to the transdiagnostic PEP model.
  • Willingness to begin taking an AP (regardless of type and dose, or change in type and dose during the study).
  • Ability to read and express themselves in French or English.
  • Capable of understanding and signing consent.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, childbirth in the last 6 months, or breastfeeding.
  • Presence of a metallic object in the body that is incompatible with MRI.
  • Any use of APs for more than 2 continuous weeks in the past year and/or 6 weeks in a lifetime (except for aripiprazole if taken at less than 2.5 mg/day or quetiapine at less than 50 mg/day, regardless of duration or timing of the prescription).
  • The following comorbidities: psychosis + borderline or intellectual disability, autism spectrum disorder, substance use disorder with decompensation, psychosis induced by a medical condition, or psychosis induced by drug use or withdrawal.
  • Type 1 diabetes.
  • Uncontrolled acute suicidal ideation.
  • Other conditions that could interfere with participation according to the judgment of the qualified physician.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
18 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • First episode psychosis

    Individuals aged 18 to 35 from the Estrie region who have been evaluated by the "PEP team" (First episode psychosis intervention Team of the pschiatric department of the CIUSSS de l'Estrie-CHUS) and wish to start an antipsychotic (AP) for the treatment of a first episode of psychosis.

    Drug: Antipsychotic drugs

Interventions

06

What researchers measure

Primary outcomes

  1. Cerebral metabolic rate of glucose and acetotacetate

    Cerebral metabolic rate of glucose and acetotacetate(μmol/100 g/min) quantified with PET scan with 18F-FDG tracer and 11C-AcAc

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

  2. Net inflow of glucose and acetoacetate

    Net inflow of glucose and acetoacetate (k) as measured by PET scan with 18F-FDG and 11C-AcAc traceur (Kglu and Kacac, min-1)

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

Secondary outcomes

  1. % of change in Brief Psychiatric Rating Scale

    % of change in the Brief psychiatric Rating Scale (raw score after/raw score before\*100)

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

  2. Concentration of glucose

    Concentration of glucose measure in fasting plasma

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

  3. Concentration of insuline

    Concentration of insulinemeasure in fasting plasma

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

  4. Concentration of Hemoglobin A1C

    Concentration of HbA1C measured in fasting plasma

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

Other outcomes

  1. Global brain volume measured by MRI

    Global brain volumes measured as global brain volumes (ml) measured by MRI

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

  2. Thicknesses of the cerebral cortex

    Thicknesses of the cerebral cortex (mm) measured by MRI

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

  3. Depression status measured by the score of "Calgary Depression Scale for Schizophrenia

    Score of "Calgary Depression Scale for Schizophrenia" (CDSS) . Min score 0, maximum score 27 with worsening of the patient condition with hight value

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

  4. Functionning level measured by the score of the Global Assessment of functionning

    Score of the "Global Assessment of functionning (GAF). Min score 0, maximum score 100, with worsening of the patient condition with higher value

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

  5. Side effet score measured by the Side Effect Rating Scale

    Score on the "Side Effect Rating Scale" UKU. Min score 0, maximum score 135 (female) 129 (male), with worsening of the side effect with higher value

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

  6. Alcohol consumption measured by the score of the Alcohol Use Disorders Identification Test -AUDIT

    Alcoohol consumption as measured by the score of the Alcohol Use Disorders Identification Test AUDIT. Min score 0, maximum score 40, with higher alcool consumption with higher value of the score

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

  7. Drug consumption measured by the score of the Drug Use Disorders Identification Test -DUDIT

    Drug consumption as measured by the score of the Drug Use Disorders Identification Test DUDIT. Min score 0, maximum score 40, with higher alcool consumption with higher value of the score

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

  8. Average weekly hours of sport/exercise per day

    Average weekly hours of sport/exercise per day" as measured by question 4 of the Simple Physical Activity questionnaire SIMPAQ (hour)

    Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, Beal MF, Bergersen LH, Brinton RD, de la Monte S, Eckert A, Harvey J, Jeggo R, Jhamandas JH, Kann O, la Cour CM, Martin WF, Mithieux G, Moreira PI, Murphy MP, Nave KA, Nuriel T, Oliet SHR, Saudou F, Mattson MP, Swerdlow RH, Millan MJ. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020 Sep;19(9):609-633. doi: 10.1038/s41573-020-0072-x. Epub 2020 Jul 24. PubMed 32709961 ↗
  • Croteau E, Castellano CA, Richard MA, Fortier M, Nugent S, Lepage M, Duchesne S, Whittingstall K, Turcotte EE, Bocti C, Fulop T, Cunnane SC. Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer's Disease. J Alzheimers Dis. 2018;64(2):551-561. doi: 10.3233/JAD-180202. PubMed 29914035 ↗
  • Croteau E, Castellano CA, Fortier M, Bocti C, Fulop T, Paquet N, Cunnane SC. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease. Exp Gerontol. 2018 Jul 1;107:18-26. doi: 10.1016/j.exger.2017.07.004. Epub 2017 Jul 12. PubMed 28709938 ↗
  • Agarwal SM, Kowalchuk C, Castellani L, Costa-Dookhan KA, Caravaggio F, Asgariroozbehani R, Chintoh A, Graff-Guerrero A, Hahn M. Brain insulin action: Implications for the treatment of schizophrenia. Neuropharmacology. 2020 May 15;168:107655. doi: 10.1016/j.neuropharm.2019.05.032. Epub 2019 May 29. PubMed 31152767 ↗
  • Fortier M, Castellano CA, St-Pierre V, Myette-Cote E, Langlois F, Roy M, Morin MC, Bocti C, Fulop T, Godin JP, Delannoy C, Cuenoud B, Cunnane SC. A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6-month RCT. Alzheimers Dement. 2021 Mar;17(3):543-552. doi: 10.1002/alz.12206. Epub 2020 Oct 26. PubMed 33103819 ↗
  • Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Boles Ponto LL, Hichwa RD. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet. 1997 Jun 14;349(9067):1730-4. doi: 10.1016/s0140-6736(96)08258-x. PubMed 9193383 ↗
  • Townsend L, Pillinger T, Selvaggi P, Veronese M, Turkheimer F, Howes O. Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of 18FDG-PET studies in schizophrenia. Psychol Med. 2023 Aug;53(11):4880-4897. doi: 10.1017/S003329172200174X. Epub 2022 Jun 22. PubMed 35730361 ↗
  • Henkel ND, Wu X, O'Donovan SM, Devine EA, Jiron JM, Rowland LM, Sarnyai Z, Ramsey AJ, Wen Z, Hahn MK, McCullumsmith RE. Schizophrenia: a disorder of broken brain bioenergetics. Mol Psychiatry. 2022 May;27(5):2393-2404. doi: 10.1038/s41380-022-01494-x. Epub 2022 Mar 9. PubMed 35264726 ↗
  • Lee J, Xue X, Au E, McIntyre WB, Asgariroozbehani R, Panganiban K, Tseng GC, Papoulias M, Smith E, Monteiro J, Shah D, Maksyutynska K, Cavalier S, Radoncic E, Prasad F, Agarwal SM, Mccullumsmith R, Freyberg Z, Logan RW, Hahn MK. Glucose dysregulation in antipsychotic-naive first-episode psychosis: in silico exploration of gene expression signatures. Transl Psychiatry. 2024 Jan 10;14(1):19. doi: 10.1038/s41398-023-02716-8. PubMed 38199991 ↗
  • Agarwal SM, Stogios N, Ahsan ZA, Lockwood JT, Duncan MJ, Takeuchi H, Cohn T, Taylor VH, Remington G, Faulkner GEJ, Hahn M. Pharmacological interventions for prevention of weight gain in people with schizophrenia. Cochrane Database Syst Rev. 2022 Oct 3;10(10):CD013337. doi: 10.1002/14651858.CD013337.pub2. PubMed 36190739 ↗
  • Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, Muller DJ, Hahn MK. The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. Front Neurosci. 2018 Jan 22;11:741. doi: 10.3389/fnins.2017.00741. eCollection 2017. PubMed 29403343 ↗
  • Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015 Oct;14(3):339-47. doi: 10.1002/wps.20252. PubMed 26407790 ↗
  • Sabe M, Pallis K, Solmi M, Crippa A, Sentissi O, Kaiser S. Comparative Effects of 11 Antipsychotics on Weight Gain and Metabolic Function in Patients With Acute Schizophrenia: A Dose-Response Meta-Analysis. J Clin Psychiatry. 2023 Feb 8;84(2):22r14490. doi: 10.4088/JCP.22r14490. PubMed 36752753 ↗
  • Fan Z, Wu Y, Shen J, Ji T, Zhan R. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res. 2013 Nov;47(11):1549-56. doi: 10.1016/j.jpsychires.2013.07.011. Epub 2013 Aug 15. PubMed 23953755 ↗
  • Correll CU, Hojlund M, Graham C, Todtenkopf MS, McDonnell D, Simmons A. Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis. Int J Neuropsychopharmacol. 2023 Jul 31;26(7):451-464. doi: 10.1093/ijnp/pyad029. PubMed 37326421 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2027, 37 months after the start.

Of 89 non-industry observational studies under Metabolic Diseases, half reached primary completion within 135 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 339. This study's planned 37 months is below that.

Counting every sponsor, half of 101 studies reached it within 135 months; a quarter within 23 and three quarters within 339.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Nov 2026 → Dec 2027 and completion Jun 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2024
First posted
Oct 21, 2024
StartActual
Nov 1, 2024
Primary completionEst.
Dec 1, 2027was Nov 2026
CompletionEst.
Jun 1, 2028was Jun 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
Hotel-Dieu CIUSSS de l'Estrie-CHUS is now Recruiting
Oct 26, 2026
Primary completion
Nov 1, 2026→Dec 1, 2027
Oct 26, 2026
Study completion
Jun 1, 2027→Jun 1, 2028
Oct 26, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Hotel-Dieu CIUSSS de l'Estrie-CHUS · Sherbrooke, CanadaContact added m•••@usherbrooke.ca · •••8134
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    Hotel-Dieu CIUSSS de l'Estrie-CHUS is now Recruiting
    Primary completion Nov 1, 2026→Dec 1, 2027
    Study completion Jun 1, 2027→Jun 1, 2028
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Hotel-Dieu CIUSSS de l'Estrie-CHUS · Sherbrooke, CanadaContact added m•••@usherbrooke.ca · •••8134
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06651112
Collaborators
Baszucki Brain Research Fund
Responsible party
Stephen Cunnane (Professor, Université de Sherbrooke) — Principal investigator
First posted
Oct 21, 2024
Start date
Nov 1, 2024
Primary completion
Dec 1, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Melanie Fortier, M.Sc
Contact
melanie.fortier2@usherbrooke.ca
8195758134
Stephen Cunnane, Ph.D.
Contact
melanie.fortier2@usherbrooke.ca
819-780-2220 ext. 45670
Stephen Cunnane, Ph.D
principal investigator · Université de Sherbrooke
Kevin Zemmour, MD
principal investigator · Université de Sherbrooke
Maggie Hahn, MD
principal investigator · University of Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion